title: [Anogenital warts: a new way of solving the common problem of urology (results of long-term follow-up)].
abstract: OBJECTIVE
  To evaluate the effectiveness of combined use of the imiquimod 5% cream and vaccination against human papillomavirus (HPV) using a quadrivalent recombinant vaccine to achieve long-term clinical remission of chronic HPV infection manifested by anogenital warts.
  
  
  METHODS
  The study comprised 36 patients, including 22 men, aged 26.4+/-4.1 years, who had from 1 to 5 anogenital warts. Participants of the study were vaccinated by quadrivalent recombinant vaccine under a 3-dose scheme 0-2-6 months co-administered with imiquimod 5% cream three times per week up to 16 weeks. The follow-up period was 2 years.
  
  
  RESULTS
  Complete disappearance of genital warts within 1 year from baseline was observed in 34 (94.4%) patients. Two patients with anogenital warts after 1 year were treated for 1 year 3 months and 1 year and 4 months with Solcoderm which lead to the complete disappearance of genital warts. There were no recurrences of genital warts during the 2 years of follow-up.
  
  
  CONCLUSIONS
  Vaccination with a recombinant quadrivalent vaccine concurrently with using imiquimod 5% cream results in prolonged clinical remission of chronic HPV infection manifested by anogenital warts in at least 94.4% of the cases (2 year follow-up).
authors.affiliation: Samara State Medical University, Samara, Russia.
authors.forename: A D
authors.initials: AD
authors.lastname: Protasov
authors.affiliation: Samara State Medical University, Samara, Russia.
authors.forename: I S
authors.initials: IS
authors.lastname: Lipatov
authors.affiliation: I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
authors.forename: M P
authors.initials: MP
authors.lastname: Kostinov
authors.affiliation: Samara State Medical University, Samara, Russia.
authors.forename: Yu V
authors.initials: YV
authors.lastname: Tezikov
authors.affiliation: I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
authors.forename: A D
authors.initials: AD
authors.lastname: Shmitko
authors.affiliation: I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
authors.forename: D V
authors.initials: DV
authors.lastname: Pakhomov
authors.affiliation: I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
authors.forename: D A
authors.initials: DA
authors.lastname: Blagovidov
authors.affiliation: Samara State Medical University, Samara, Russia.
authors.forename: A V
authors.initials: AV
authors.lastname: Zhestkov
authors.affiliation: I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
authors.forename: A A
authors.initials: AA
authors.lastname: Ryzhov
authors.affiliation: Samara Regional Center for Prevention and Control of AIDS and Infectious Diseases.
authors.forename: E V
authors.initials: EV
authors.lastname: Vekhova
mesh_terms: D019342:Acetic Acid / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000634:Aminoquinolines / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001004:Anus Diseases / Q000628:therapy*; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000628:therapy*; D003300:Copper / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077271:Imiquimod; D007773:Lactates / Q000627:therapeutic use; D008297:Male; D009566:Nitrates / Q000627:therapeutic use; D009824:Ointments; D030361:Papillomavirus Infections / Q000628:therapy*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D014614:Vaccines, Synthetic; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D003879:Dermatologic Agents; D007773:Lactates; D009566:Nitrates; D009824:Ointments; D053918:Papillomavirus Vaccines; D014614:Vaccines, Synthetic; D003300:Copper; D000077271:Imiquimod; D019342:Acetic Acid
keywords: HPV infection; genital warts; imiquimod; the combined use of; vaccination; vaccine against human papillomavirus quadrivalent recombinant